Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops Legio X, a COVID-19 rapid antigen test that validating the Gemina Surface Chemistry on this platform; and LEGIO X, an influenza AB multiplex lateral flow test. It is also developing a pipeline of products for the diagnosis of infectious respiratory diseases. The company was incorporated in 2017 and is headquartered in Burnaby, Canada.
Stock data | 2024 | Change |
---|---|---|
Price | $0.49172842541533485 | N/A |
Market Cap | $36.06M | N/A |
Shares Outstanding | 73.33M | N/A |
Employees | 6.00 | N/A |